In this report, guidelines for the evaluation, medical and surgical management of renal cell carcinoma is presented. It is categorized according to the stage of the disease using the tumor node metastasis staging system, 7 th edition. The recommendations are presented with supporting evidence level.
INTRODUCTION
Renal cancer represents the third common genitourinary cancer in Saudi Arabia after urinary bladder and prostate. [1] It accounts for 2.8% of all male cancers and 1.9% of all female cancers. In 2006, a total of 111 cases where diagnosed in males and 78 cases in females. The Age Standardized Rate in males was 2.4 per 100,000 and in females was 1.5 per 100,000 populations.
All cases of renal cell carcinoma should preferably be seen or discussed in a multidisciplinary forum The American Joint Commission on Cancer Staging TNM 7 th edition was used
RISK STRATIFICATION FOR METASTATIC RCC
The Memorial Sloan Kettering cancer center risk classification for metastatic disease will be used: [3] Risk factors are: 3.1.
A Karnofsky performance status (KPS) of <80% 3.2.
Serum lactic dehydrogenase (LDH) level >1.5 times the upper limit of normal 3.3.
Corrected serum calcium >10 mg/dL (2.5 mmol/L) 3.4.
Hemoglobin concentration below the lower limit of normal 3.5.
No prior nephrectomy (i.e., no disease-free interval)
Each of the above gives a score of one. Patients will be classified according to the total score as follows: 0 points Low risk Potentially resectable primary with solitary metastasis or multiple resectable lung metastasis: those patients should undergo primary nephrectomy and resection of the metastatic lesion/s (EL-2). [4] Following complete resection no further therapy is indicated (EL-3).
4.2.2.
Potentially resectable primary and multiple metastasis: those patients should undergo resection of the primary tumor if in good performance status (EL-1), [5, 6] then should start systemic therapy as follows: 4.2.2.1.
Clear cell histology, good and intermediate risk:
options are Sunitinib [7] (EL-1), Bevacizumab and Interferon α-2a [8, 9] or pazopanib [10] (EL-1).
4.2.2.2.
C l e a r c e l l h i s t o l o g y a n d p o o r r i s k : Temsirolimus [11] (EL-1) 4.2.2.3.
Non-clear cell histology: Temsirolimus (EL-2) [12] or Sunitinib [13] (EL-2), or Sorafenib [14] (EL-2). Medullary and collecting duct carcinoma should be treated with platinum-based chemotherapy [15, 16] Second-line therapy post-TKI failure: Everolimus (EL-1) [20, 21] 
